Skip to main content
OpenTrials
Completed

NCT Number: NCT02215733

The Use of Angiotensin Receptor Blockers and the Risk of Cancer

The primary objective of this study was to assess whether angiotensin blockers (ARBs) and telmisartan in particular, are associated with an increased overall risk of the four most common cancers, namely, lung, colorectal, breast and prostate cancers. A secondary objective was to explore these effects separately for each of the four cancers and in combination with angiotensin-converting-enzyme-inhibitors (ACEIs).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Neoplasm Neoplasms

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients prescribed an antihypertensive agent between 01-JAN-1995 and 31-DEC-2008 with at least two years of up-to-standard medical history in United Kingdom's General Practice Research Database (GPRD)

Exclusion criteria

  • History of cancer at any time prior to cohort entry

Treatment and study plan

ARB

Drug

other than telmisartan

ACEI

Drug

Beta-blockers

Drug

Diuretics

Drug

Telmisartan

Drug

Primary outcomes

  1. Number of patients with occurrences of lung, colorectal, breast and prostate cancers related to use of ARBs

    Time frame: 16 years

  2. Determination of dose-response in terms of ARB duration of use and cumulative dose and the risk of lung, colorectal, breast and prostate cancers combined

    Time frame: 16 years

  3. Ratio of occurrence of lung, colorectal, breast and prostate cancers related to use of ARBs, relative to beta-blockers and diuretics

    Time frame: 16 years

  4. Ratio of occurrence of lung, colorectal, breast and prostate cancers related to use of telmisartan, relative to beta-blockers and diuretics

    Time frame: 16 years

  5. Ratio of occurrence of lung, colorectal, breast and prostate cancers related to use of telmisartan relative to other ARBs

    Time frame: 16 years

Secondary outcomes

  1. Number of patients with occurrences of lung cancer related to use of ARBs alone

    Time frame: 16 years

  2. Number of patients with occurrences of colorectal cancer related to use of ARBs alone

    Time frame: 16 years

  3. Number of patients with occurrences of breast cancer related to use of ARBs alone

    Time frame: 16 years

  4. Number of patients with occurrences of prostate cancer related to use of ARBs alone

    Time frame: 16 years

  5. Number of patients with occurrences of lung cancer related to use of ARBs with ACEI

    Time frame: 16 years

  6. Number of patients with occurrences of colorectal cancer related to use of ARBs with ACEI

    Time frame: 16 years

  7. Number of patients with occurrences of breast cancer related to use of ARBs with ACEI

    Time frame: 16 years

  8. Number of patients with occurrences of prostate cancer related to use of ARBs with ACEI

    Time frame: 16 years

  9. Ratio of occurrence of lung cancer related to use of telmisartan relative to other ARBs

    Time frame: 16 years

  10. Ratio of occurrence of colorectal cancer related to use of telmisartan relative to other ARBs

    Time frame: 16 years

  11. Ratio of occurrence of breast cancer related to use of telmisartan relative to other ARBs

    Time frame: 16 years

  12. Ratio of occurrence of prostate cancer related to use of telmisartan relative to other ARBs

    Time frame: 16 years

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Important dates

Study start
2011
Primary completion
2012
First posted
Aug 13, 2014
Registry last updated
Aug 13, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.